Skandinaviska Enskilda Banken Ab (Publ) Xencor Inc Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$16.53 - $21.42 $171,912 - $222,768	10,400 New	10,400 $220,000
Q4 2021 Feb 10, 2022	SELL	$33.67 - $43.44 $1.26 Million - $1.63 Million	-37,500 Closed	0 $0
Q3 2021 Nov 10, 2021	BUY	$30.65 - $35.68 $1.15 Million - $1.34 Million	37,500 New	37,500 $1.23 Million
Q2 2020 Aug 13, 2020	SELL	$27.76 - $33.42 $1.54 Million - $1.85 Million	-55,400 Closed	0 $0
Q1 2020 May 13, 2020	SELL	$20.69 - $37.79 $91,036 - $166,276	-4,400 Reduced 7.36%	55,400 $1.66 Million
Q4 2019 Feb 14, 2020	BUY	$32.75 - $41.43 $835,125 - $1.06 Million	25,500 Added 74.34%	59,800 $2.06 Million
Q3 2019 Nov 08, 2019	BUY	$33.73 - $46.27 $1.16 Million - $1.59 Million	34,300 New	34,300 $1.16 Million

216

71.5M

2.5K

7.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.23B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.